A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC")

Trial Profile

A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC")

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs L-DOS 47 (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Helix BioPharma
  • Most Recent Events

    • 11 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 11 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 25 Jul 2017 According to a Helix BioPharma media release, screening in the third dosing cohort has been initiated.Patients enrolled in this cohort will recieve 1.50 micrograms/kg of L-DOS47.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top